Tags

Type your tag names separated by a space and hit enter

Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects.
J Neurol Sci. 2009 Jan 15; 276(1-2):18-21.JN

Abstract

Sporadic Parkinson's disease (PD) is a frequent neurodegenerative movement disorder. Both environmental and genetic factors have been studied in the etiology of PD. Among genetic factors, increasing evidences suggest that deletion/insertion (D/I) gene polymorphism of the angiotensin I-converting enzyme (ACE) may be involved in the pathogenesis of PD and in the occurrence of the adverse effects of chronic L-dopa therapy. We investigated this hypothesis by evaluating the frequency of the ACE gene D/I polymorphism in 120 Italian PD patients and 132 controls. Out of the 120 PD patients, 91 were under chronic L-dopa treatment. Our results revealed no difference in ACE I/D genotype (chi(2)=0.79, p=0.66) and allele (chi(2)=0.34, p=0.56) frequencies between PD and controls. We also failed to observe any significant association with the occurrence of L-dopa-induced adverse effects in long-term treated PD patients, thereby excluding the presence of an association between ACE I/D genotypes and the genetic susceptibility to PD and the development of adverse effect of chronic L-dopa therapy.

Authors+Show Affiliations

Dipartimento di Medicina Sperimentale e Patologia, Università degli Studi La Sapienza, Rome, Italy. esterina.pascale@uniroma1.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18805557

Citation

Pascale, Esterina, et al. "Genetic Polymorphism of Angiotensin-Converting Enzyme Is Not Associated With the Development of Parkinson's Disease and of L-dopa-induced Adverse Effects." Journal of the Neurological Sciences, vol. 276, no. 1-2, 2009, pp. 18-21.
Pascale E, Purcaro C, Passarelli E, et al. Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects. J Neurol Sci. 2009;276(1-2):18-21.
Pascale, E., Purcaro, C., Passarelli, E., Guglielmi, R., Vestri, A. R., Passarelli, F., & Meco, G. (2009). Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects. Journal of the Neurological Sciences, 276(1-2), 18-21. https://doi.org/10.1016/j.jns.2008.08.017
Pascale E, et al. Genetic Polymorphism of Angiotensin-Converting Enzyme Is Not Associated With the Development of Parkinson's Disease and of L-dopa-induced Adverse Effects. J Neurol Sci. 2009 Jan 15;276(1-2):18-21. PubMed PMID: 18805557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects. AU - Pascale,Esterina, AU - Purcaro,Carlo, AU - Passarelli,Emanuela, AU - Guglielmi,Renzo, AU - Vestri,Anna Rita, AU - Passarelli,Francesca, AU - Meco,Giuseppe, Y1 - 2008/09/20/ PY - 2008/02/15/received PY - 2008/07/03/revised PY - 2008/08/13/accepted PY - 2008/9/23/pubmed PY - 2009/3/18/medline PY - 2008/9/23/entrez SP - 18 EP - 21 JF - Journal of the neurological sciences JO - J Neurol Sci VL - 276 IS - 1-2 N2 - Sporadic Parkinson's disease (PD) is a frequent neurodegenerative movement disorder. Both environmental and genetic factors have been studied in the etiology of PD. Among genetic factors, increasing evidences suggest that deletion/insertion (D/I) gene polymorphism of the angiotensin I-converting enzyme (ACE) may be involved in the pathogenesis of PD and in the occurrence of the adverse effects of chronic L-dopa therapy. We investigated this hypothesis by evaluating the frequency of the ACE gene D/I polymorphism in 120 Italian PD patients and 132 controls. Out of the 120 PD patients, 91 were under chronic L-dopa treatment. Our results revealed no difference in ACE I/D genotype (chi(2)=0.79, p=0.66) and allele (chi(2)=0.34, p=0.56) frequencies between PD and controls. We also failed to observe any significant association with the occurrence of L-dopa-induced adverse effects in long-term treated PD patients, thereby excluding the presence of an association between ACE I/D genotypes and the genetic susceptibility to PD and the development of adverse effect of chronic L-dopa therapy. SN - 0022-510X UR - https://www.unboundmedicine.com/medline/citation/18805557/Genetic_polymorphism_of_Angiotensin_Converting_Enzyme_is_not_associated_with_the_development_of_Parkinson's_disease_and_of_L_dopa_induced_adverse_effects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(08)00430-9 DB - PRIME DP - Unbound Medicine ER -